Oxymorphone ER: Start Phase III

The companies will begin this month a 12-week, double-blind, placebo-controlled, U.S. Phase III

Read the full 135 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE